心血管疾患におけるプロテアゼ活性化受容体
Andrew J Leger1, Lidija Covic, Athan Kuliopulos
1Hemostasis and Thrombosis Laboratory, Division of Hematology/Oncology, Molecular Oncology Research Institute, Tufts-New England Medical Center, Boston, MA 02111, USA.
Circulation
|September 6, 2006
まとめ
プロテアゼ活性化受容体-1 (PAR1) を標的とする小分子阻害剤は,血栓症の治療に有望であることが示されています. 新しいペプドゥチン阻害剤は,タンパク質酵素シグナル伝達におけるPAR1およびPAR4のこれまで未知の役割を明らかにしています.
科学分野:
- 心血管医学 心血管医学
- 分子薬理学 分子薬理学
- プロテアゼシグナル伝達
背景:
- 血栓症は,血小板と血管細胞の活性化を伴うため,血栓素とその受容体の重要性を強調しています.
- プロテアゼ活性化受容体 (PAR) 経由のトロンビンシグナリングは,血小板活性化,炎症,および血管機能に影響します.
- PAR1とPAR4は,動物モデルにおける血栓形成と再形成の予防のための有効な標的である.
研究 の 目的:
- PAR1.1を標的とする小分子阻害剤の分子および薬理学的基礎を説明する.
- 新しい細胞浸透阻害剤 (ペプドゥチン) を用いて,プロテアゼシグナル伝達におけるPAR1とPAR4の役割を調査する.
主な方法:
- 小分子 PAR1 阻害剤の開発と特徴付け.
- ペプドゥチンを用いて,プロテアゼシグナル伝達におけるPAR1とPAR4の機能を調査する.
主要な成果:
- PAR1を標的にする小分子の分子および薬理学的プロファイルを確立しました.
- ペプドゥチンの研究により,プロテアゼシグナル伝達における PAR1 と PAR4 の新しい役割が特定されました.
結論:
- PAR1を標的とする小分子阻害剤は,血栓形成の治療戦略を提供します.
- ペプドゥチンは,細胞シグナル伝達における PAR1 と PAR4 の複雑な役割に関する新しい洞察を提供します.
関連する概念動画
Enzyme-linked Receptors
64.6K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
64.6K
G-Protein Gated Ion Channels
5.5K
GPCRs are primarily responsible for our sense of smell, taste, and vision. The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory...
Sensory...
5.5K
Transducer Mechanism: Enzyme-Linked Receptors
4.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.4K
Adrenergic Receptors: ɑ Subtype
2.7K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
765
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
765


